AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis

pharmafile | December 10, 2020 | News story | Research and Development AbbVie, upadacitinib 

AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate to severe ulcerative colitis in adult patients, showing that the therapy met its primary and secondary endpoints.

According to the Adapted Mayo Score, 26% of patients receiving AbbVie’s therapy achieved clinical remission after eight weeks of treatment, whereas just 5% of patients receiving placebo achieved the same. With that achievement, the therapy passed its main goal in the trial.

After the same period, 36% of patients receiving upadacitinib saw endoscopic improvement in the study compared to 7% of placebo patients, and 30% saw histologic-endoscopic mucosal improvement compared to 7% respectively.

Overall, upadacitinib presented an overall response rate of 73% compared to just 27% with placebo.

“Ulcerative colitis is a complex disease to manage, and many patients do not achieve relief from symptoms,” commented Dr Silvio Danese, Lead Investigator on the study and Head of the Inflammatory Bowel Diseases Centre at Humanitas Research Hospital in Italy. “I am excited about these positive results showing the potential of upadacitinib to alleviate symptoms and control mucosal inflammation in patients with moderate to severe ulcerative colitis.”

According to AbbVie, the full results from the study will be incoming at a future medical event and published in a peer-reviewed journal.

Matt Fellows

Related Content

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has …


AbbVie funds Mitokinin’s Parkinson’s research with option to buy

AbbVie has landed an option to buy neurodegenerative disease-focused biotech Mitokinin following completion of investigational …


AbbVie’s rheumatoid arthritis drug Rinvoq approved for NHS Scotland

The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for …

Latest content